German CML Trial: Intermittent Dasatinib Noninferior, Fewer Effusions
Among the 260 patients evaluated in the German Chronic Myeloid Leukemia Alliance randomized trial, rates reached 81% with continuous dosing and 78% with intermittent dosing.
Although continuous treatment showed a 3-percentage-point difference favoring continuous treatment, intermittent dosing met the prespecified noninferiority criterion, with a 15% margin (P = .009).
Overall, 206 patients, representing 79% with a 95% CI of 74% to 84%, achieved major molecular response at 24 months. For patients receiving first-line dasatinib, major molecular response rates at 24 months were comparable at 79% with continuous dosing and 81% with intermittent dosing, meeting the noninferiority criterion.
Among patients receiving second-line or later treatment, rates were 87% and 62.5% respectively, with a P value of .039, and noninferiority was not established. Investigators emphasized that these subgroup analyses were not prespecified and should be considered exploratory.
While intermittent dosing maintained molecular responses, it did not demonstrate superiority for the primary toxicity end point. Patients experienced grade 2 to 4 adverse events at rates of 58% for those on continuous dasatinib and 56% for those on intermittent treatment; meanwhile, the median cumulative toxicity scores were 2 in both arms, resulting in a P value of .83.
However, an exploratory post hoc analysis identified differences in pleural and pericardial effusions, which are known dasatinib-associated toxicities. These events occurred in 21 of 130 patients, or 16%, receiving continuous dosing compared with 10 of 125 patients, or 8%, receiving intermittent dosing, yielding a P value of .0464. Regarding the 24-month cumulative incidence rates, a distinct post hoc time-to-event analysis reported figures of 16% and 7% respectively, with a P value of .014.
Health-related quality of life also favored intermittent dosing. Of the 217 patients who completed evaluable questionnaires, those receiving dasatinib as a first-line therapy primarily showed clinically meaningful improvements, while symptom worsening was seen in patients on later-line therapy; ultimately, the intermittent regimen resulted in better outcomes for overall health-related quality of life.
At a median follow-up of 43 months, no patients in either treatment group experienced progression to accelerated or blast phase chronic myeloid leukemia, and no chronic myeloid leukemia–related deaths were reported. Overall survival was 98% at 2 years with a 95% CI of 95% to 99%, and 97% at 5 years with a 95% CI of 93% to 98%, with no statistically significant difference observed between treatment groups at a P value of .16.
The investigators said that treatment tolerability and health-related quality of life remain important considerations as patients with chronic myeloid leukemia increasingly achieve long-term disease control with tyrosine kinase inhibitors. When assessing potential changes to a treatment regimen, it is vital to differentiate between disease resistance and tyrosine kinase inhibitor intolerance, because the latter might justify adjusting the dose instead of switching therapies right away.
In their conclusion, LaRosée et al said that intermittent dasatinib dosing achieved “noninferior molecular efficacy with favorable effects on HRQOL and selected toxicities.”